Editor in Chief Dr. Rahul Banerjee's April Letter from the Editor explains what the oncology field can learn from "The White Lotus."

Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer, Djordje Atanackovic, Shebli Atrash, Veronika Bachanova, Amer M. Beitinjaneh, Evg

Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer, Djordje Atanackovic, Shebli Atrash, Veronika Bachanova, Amer M. Beitinjaneh, Evg

Rahul Banerjee: Financial Toxicity Is the First Side Effect of Lenalidomide in Multiple Myeloma / cancer, Financial Toxicity of Drugs, OncoDaily, Oncology

Rahul Banerjee: Median patient-reported hair loss with a scalp cooling device during ASCT for myeloma / cancer, Cancer Therapy Advisor, MM, multiple myeloma,

Thankfully, it's time for an actual expert to join us again on Bloody Minded! We are thrilled to be sitting down and chatting with A/Prof. Tracy King , Myeloma CNC from RPA Hospital in Sydney, Co-Fou...

This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell therapy in France between 2018 and 2024 shows th...

Subcutaneous isatuximab plus Pd led to a noninferior ORR and observed concentration before dosing at steady state vs IV isatuximab plus Pd in RRMM.

Key PointsDexamethasone dose reductions <40 to 60 mg weekly are common in multiple myeloma, even for patients enrolled on clinical trials.In our large a

FDA approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib, lenalidomide, and dexamethasone for adults with diagnosed multiple myeloma

A woman with aggressive refractory systemic lupus erythematosus was treated with a short course of the bispecific antibody teclistamab (anti–B-cell maturation antigen and anti-CD3) and had a drug-...